2026-09-04 · 2026-09 / week-1

Docusign prices 9% growth, but IAM cash conversion is the next test

Docusign prices 9% growth, but IAM cash conversion is the next test

Summary: U.S. long Watchlist, not trade-qualified. Docusign, Inc. (NASDAQ: DOCU) closed at $65.97 on the regular-session tape on 2026-09-03 20:00:00 UTC. An after-hours market-structure snapshot later showed $69.25 at 2026-09-03 20:59:30 UTC, with a separate displayed bid of $69.51, ask of $69.73, and spread of $0.22. Another finance-feed observation at 2026-09-03 23:18:25 UTC still printed $65.97, so the current quote state is not reconciled and none of these observations is an executable entry. The fresh Q2 fiscal 2027 filing reported $875.7 million of revenue, up 9%, Intelligent Agreement Management (IAM) at 15.1% of ARR versus 12.6% in Q1, $295.8 million of free cash flow at a 34% margin, $306.5 million of repurchases, and 193 million diluted shares versus 211 million a year earlier. The less comfortable fact is that Q2 stock-based compensation was $148.6 million, inside operating cash flow. The long case is that a cash-generative agreement platform with rising IAM mix, a higher FY27 guide, and a shrinking diluted share count is still valued as a low-growth software asset. The countercase is that the 9% guide is modest, IAM adoption has not yet been translated into paid-agent revenue, and the headline FCF is materially supported by stock compensation and working-capital timing. Using the more conservative $69.25 after-hours reference, the price-only map is $90 top / $78 base / $63 bottom at 25% / 55% / 20%, producing a weighted target of $78.00 and a 12.64% gross reference return. The base case clears +10%, but the credible adverse case is -9.03%, the gross ratio is only 1.40:1, and the entry is unverified. Keep entry.price null and execution.can_execute false. This is research, not personalized financial advice.

Run timestamp: 2026-09-04T07:32:07+08:00 (Asia/Singapore). Quote time, release time, filing period, and signal generation time are separate.

Opportunity Ranking

Rank Candidate Direction Mispricing Evidence Freshness Catalyst Window Positioning 10/5 Status Tradeability Main Rejection Risk
1 Docusign (DOCU) Long A fresh release raised revenue, ARR, and IAM guidance while showing 34% quarterly FCF and materially lower diluted shares. The market reaction is positive but still leaves a plausible cash-flow and IAM rerating case Sep. 3 SEC 8-K exhibit and company release; same-session regular and after-hours observations First regular session after the print, Sep. 4 10-Q expected by the company, Q3 guide conversion, and FY27 IAM mix 15.42M shares short, 8.12% of float, 5.3 DTC as of Aug. 14; institutional ownership is high, but data lag and quote conflict remain Watchlist: reference-only base +12.64%, credible bottom -9.03% Regular volume was about 5.0M shares; an after-hours spread snapshot exists, but current regular-session depth, venue quality, and exit liquidity are not verified 9% growth is too slow for a rerating, IAM is product relabeling, or FCF falls after SBC and working-capital effects
2 Brady (BRC) Long FY27 adjusted EPS guidance implies 18.1% to 27.6% growth and the Honeywell IPS acquisition adds a visible accretion path, but the transaction was funded with roughly $1.6B of new borrowings and the share price did not dislocate Sep. 3 official FY26 release, 10-K, and acquisition financing 8-K IPS integration, debt reduction, first full-quarter contribution, and next earnings cycle About 700K shares short, 1.65% of float, 4.2 DTC as of Aug. 14; low crowding reduces squeeze support Watchlist: base can clear +10%, but integration and leverage keep the adverse case above 5% NYSE quote and 364K regular shares were visible; current depth and exit evidence are incomplete Financing cost, integration, or industrial demand weakens the expected EPS accretion
3 UiPath (PATH) Long Q2 revenue rose 13%, ARR 12%, and cash plus marketable securities were $1.405B, but the post-result tape ranged from $15.44 to $20.68 and leadership changes make the next path unusually volatile Sep. 3 company release and current finance-feed observation First regular session, Q3 ARR guide, new CFO transition, and FY27 operating-income conversion Current short interest and borrow were not verified for this long screen Watchlist: base can clear +10%, but the observed intraday range leaves a credible adverse move beyond 5% About 62.7M shares traded in the finance snapshot, but current venue and exit data are not reconciled Growth remains near 12% while AI competition and executive transition pressure the multiple
4 Zscaler (ZS) Long FY26 revenue and ARR each grew 25% and FY27 guidance remains profitable, but the quote was already up about 3% and Q4 FCF margin fell to 7% because of a large capex and internal-use-software step-up Sep. 3 official result and FY26 10-K First regular session, FY27 growth conversion, and capex normalization Current direct positioning and borrow were not verified Reject for this screen: strong business, but valuation, capex, and the adverse range do not fit the 10/5 long About 8.5M shares traded; current depth and exit evidence are incomplete Growth deceleration or sustained capex prevents the expected cash multiple support

The screen used mechanism-specific searches combining “agreement system of action IAM 15.1% ARR free cash flow stock compensation repurchase denominator,” “post-earnings cash yield buyback dilution AI agent paid adoption deferred revenue,” “automation platform Q2 guide enterprise software cash after SBC shares cancelled,” and “cybersecurity FY26 cash flow capex deferred revenue ARR post-close.” Generic earnings-only searches were not used. The current-week archive was scanned by filename, headline, ticker, issuer, mechanism, and direction. There is no dedicated DOCU article or signal in the current-week archive. The prior Ciena note mentioned DOCU only as a pre-result candidate; this article crosses a material evidence boundary because the Sep. 3 Q2 result, guidance, cash flow, repurchase, and IAM data are now filed.

Selected opportunity: Docusign common stock, Nasdaq.

Why this one now: DOCU has the cleanest current fundamental bridge among the screened longs. The latest filing supplies reported revenue, IAM mix, operating cash, FCF, stock compensation, cash and investments, repurchases, diluted shares, and a higher forward guide in one document. BRC has a larger EPS guide but also a newly leveraged acquisition. PATH has good cash, but its event-day price range is too wide for a defensible 5% adverse bound. ZS has the best reported growth, yet the market already paid for much of it and its latest FCF conversion was distorted by a large investment step-up.

What should surprise the reader: The relevant long argument is not that Docusign has discovered AI. It is that the company is converting a modest growth rate into cash and fewer diluted shares while the market still has to decide whether IAM is a paid expansion layer or only a new label for agreement software. The surprise would be a sustained share-count and cash-flow rerating without an acceleration in headline revenue. The risk is that the market is correctly treating 9% growth and $148.6M of quarterly SBC as a ceiling, not a discount.

Why This Is the Best Opportunity Right Now

The strongest mature counterparty argument is simple: a 9% growth software company should not receive a growth multiple merely because management attached agent language to an existing workflow. Docusign is competing for budget with Microsoft, Adobe, contract-lifecycle platforms, and internal automation tools. Its FY27 guidance calls for revenue growth of about 9% and ARR growth of 8.5% to 9.0%. The product announcement is extensive, but the release does not disclose paid-agent revenue, incremental IAM bookings, net retention for IAM cohorts, or customer-level conversion from eSignature into the new platform. If the next filing shows stable revenue, flat retention, and lower cash after compensation and working capital, the current price can be correct or generous.

The long case survives because the operating evidence is more concrete than the product language. Q2 revenue was $875.746 million, up from $800.636 million. Operating cash flow was $334.546 million, up from $246.073 million, and reported FCF was $295.757 million, up from $217.648 million. Docusign repurchased $306.5 million of common stock during the quarter, versus $201.5 million in the prior-year quarter. Non-GAAP diluted weighted-average shares fell from 210.956 million to 193.117 million. These are real period results, not an addressable-market estimate. Docusign Q2 fiscal 2027 SEC exhibit

IAM represented 15.1% of total ARR at July 31, 2026, compared with 12.6% at April 30. Management expects IAM to represent approximately 18% to 19% of total ARR exiting FY27. The Q3 guide is $886 million to $890 million of revenue, with a non-GAAP operating margin of 31.3% to 31.7%. FY27 revenue is guided to $3.499 billion to $3.507 billion, ARR growth to 8.5% to 9.0%, and non-GAAP operating margin to 31.0% to 31.5%. The guide is not a high-growth forecast. It is a test of whether a mature base can add a monetizable product layer without sacrificing cash conversion. Docusign Q2 fiscal 2027 SEC exhibit

The filing also makes the cash headline less clean. Q2 stock-based compensation was $148.604 million, and six-month stock-based compensation was $289.981 million. A simple cash-quality proxy of reported FCF less SBC is therefore about $147.153 million for Q2 and $295.211 million for the first six months. This is not GAAP, residual common cash, or a valuation floor. It is a diagnostic that asks how much of reported FCF remains after the largest disclosed non-cash compensation charge. The proxy ignores other non-cash items, the timing of collections, employee tax withholding, capitalized development, and the economic cost of dilution. The next filing must show whether actual repurchases continue to offset that dilution rather than merely authorize it.

The denominator evidence is nevertheless constructive. The official release reports 193 million diluted shares in Q2 versus 211 million a year earlier. That is an 8.5% reduction in the diluted weighted-average share count. It improves per-share economics if the operating base is stable. It can also make EPS look stronger than revenue if the business is buying back stock faster than it is growing. The correct long thesis is therefore a three-part bridge: IAM share rises, recurring cash after SBC remains positive, and repurchases translate into lower actual diluted shares. A single product launch or EPS beat is insufficient.

The balance sheet supplies resilience but not a complete EV bridge. At July 31, Docusign reported $528.161 million of cash, $249.516 million of current investments, and $195.398 million of noncurrent investments, approximately $973.1 million in total cash, cash equivalents, and investments. The same balance sheet includes $1.604 billion of current contract liabilities and $183.1 million of current and noncurrent operating lease liabilities. Contract liabilities are a funding benefit when revenue recognition follows, but they are not unrestricted cash. Because the current market-cap observation, balance sheet date, and provider denominator are not one auditable timestamp, this article does not compute enterprise value or a net-cash per-share target. The payoff uses price-only scenarios and states the limitation.

The product news is useful only as a catalyst path. Docusign launched an AI assistant, pre-built agents, Agent Studio, agent insertion into Workflow Builder, and an MCP server with integrations into Slack, Perplexity, Gemini Enterprise, Anthropic, OpenAI, and Microsoft Copilot. These capabilities can increase the value of agreement data and widen the platform's workflow footprint. They do not prove that customers paid for the features, that churn fell, or that contract value converted to cash. The cheapest test is the next Q3 filing and call: ask for paid IAM attach, incremental ARR, customer expansion, retention, and cash after SBC rather than another list of integrations.

No candidate clears the Desk's Trade-qualified standard at the screen time. DOCU ranks first because it has the most complete fresh evidence and the least balance-sheet fragility, not because its 10/5 gate passes. The publication decision is Watchlist research; reject for current execution.

Why This Can Move More Than 5% Soon

The first move has already exceeded 5% in some after-hours observations. The next move depends on whether the market accepts the result in a normal session and whether the operating bridge holds.

  1. First regular-session acceptance: The regular close was $65.97, while an after-hours snapshot displayed $69.25. The market-structure source also displayed a $69.51 bid, $69.73 ask, and $0.22 spread at 20:59:30 UTC. A separate feed later continued to print $65.97. The first normal session must reconcile this gap, establish depth and venue quality, and show that volume is not only event-driven.
  2. The Q2 10-Q: The Q2 8-K says Docusign expected to file the July 31 10-Q on September 4, 2026. That filing should reconcile investments, lease claims, contract liabilities, actual common shares, diluted shares, repurchases, stock compensation, deferred contract-acquisition costs, and operating cash. The scheduled date is management's expectation, not a settlement guarantee.
  3. IAM conversion: IAM must rise from 15.1% of ARR toward the 18% to 19% FY27 exit objective without a lower retention profile or an offsetting decline in the legacy eSignature base. The market needs paid adoption and expansion evidence, not only feature availability.
  4. Q3 guide conversion: Revenue guidance of $886 million to $890 million and operating margin guidance of 31.3% to 31.7% are the next near-term operating test. A beat with stable cash after SBC supports the long. A guide cut or a margin step-down without clear investment returns weakens it.
  5. Capital returns: The Q2 repurchase was $306.5 million. The next filing must show actual shares cancelled or retired, cash paid, and the diluted denominator after the repurchase. Authorization is not demand, and a buyback is not a floor.

The cheapest confirming observation is a regular-session quote that holds the post-result level while the 10-Q confirms cash, contract liabilities, current investments, and the diluted denominator. The cheapest disconfirming observation is a lower Q3 guide, flat IAM mix, or reported FCF that falls sharply after SBC and working-capital timing are separated.

10/5 Asymmetry Gate

The holding window is September 4, 2026 through the next reported Q3 fiscal 2027 result, with a mandatory re-underwrite after the first regular session and the Q2 10-Q. The scenario model uses the $69.25 after-hours reference because it is the latest non-stale post-result market-structure observation available before the run. It is not a verified entry.

Test Calculation or evidence Result
Reference price $69.25 DOCU after-hours observation at 2026-09-03 20:59:30 UTC Reference only
Favorable base move Long from $69.25 to $78.00: ($78.00 / $69.25) - 1 +12.64% before costs
Credible adverse move Long from $69.25 to $63.00: 1 - ($63.00 / $69.25) -9.03% before costs
Gross favorable-to-adverse ratio 12.64% / 9.03% 1.40:1, below the 2:1 requirement
Price-only weighted target 25% x $90.00 + 55% x $78.00 + 20% x $63.00 $78.00
Price-only gross expected return ($78.00 / $69.25) - 1 +12.64% before costs
Net EV Current executable entry, aligned market cap, debt, denominator, spread, slippage, and exit liquidity are incomplete Cannot compute responsibly
Measurement basis Verified entry or reference-only Reference-only
Classification 10/5 downside, economics, and execution gates Watchlist research; Reject for current trade

The base case clears the requested +10% long potential, but the credible bottom case is more than the requested 5% adverse bound. The high score of the operating evidence cannot override that failure. The current map is a research distribution, not a promise of either outcome. No probability is market-implied; these are judgmental scenario weights and total 100%.

Canonical rubric: Trade-qualified requires a verified executable entry, a favorable base-case move of at least 10%, a credible adverse move no greater than 5%, at least 2:1 gross reward to adverse risk, and all required execution gates. Watchlist means the research may be useful but the entry, economics, or evidence is incomplete. Reject means the candidate fails the hurdle or lacks a safe expression. DOCU is Watchlist research and Reject for current execution.

What Should Surprise the Reader

The first surprise is that the strongest long evidence is not the AI product list. It is the combination of a 34% reported Q2 FCF margin, a $306.5 million repurchase, and an 8.5% lower diluted weighted-average share count. If those three items persist, a 9% revenue grower can produce faster per-share cash growth than its top line suggests.

The second surprise is how much the cash-quality question matters. Q2 SBC of $148.6 million is roughly half of reported Q2 FCF. Removing it as a diagnostic leaves about $147.2 million of FCF before other adjustments. That does not make the cash flow false. It changes what the cash flow can support. The market can reasonably pay for cash generated after dilution only if repurchases actually reduce the denominator and paid adoption protects the revenue base.

The third surprise is that IAM can be both a genuine product expansion and a weak near-term valuation catalyst. Moving from 12.6% to 15.1% of ARR is meaningful. But ARR is a management-defined operating metric, not GAAP revenue, and the release does not disclose how much of the increase came from new customers, expansion, contract timing, or a reclassification of existing contracts. The next evidence must be paid attach, retention, and cash conversion.

The fourth surprise is the balance-sheet asymmetry. Cash and investments of approximately $973.1 million are meaningful against a roughly $13 billion equity value, but contract liabilities and leases are also material. The cash supports resilience. It does not create a guaranteed valuation floor. Docusign can be financially durable and still deserve a lower multiple if growth stays near 9%.

The Setup

Facts: Q2 revenue was $875.746 million, up 9% including an approximately 1.3% foreign-exchange benefit. IAM represented 15.1% of ARR. Q2 GAAP net income was $77.715 million, GAAP diluted EPS was $0.40, non-GAAP diluted EPS was $1.16, operating cash flow was $334.546 million, FCF was $295.757 million, cash and investments were $973.1 million, and common-stock repurchases were $306.5 million. Docusign Q2 fiscal 2027 SEC exhibit

Inference: The after-hours reaction may still underprice the value of a mature agreement platform that is converting IAM into a larger ARR mix while reducing the diluted share count. The inference is conditional on cash after SBC and paid IAM adoption continuing.

Assumptions: The scenario map uses a $69.25 after-hours reference, a September 4 to the next Q3 result window, and judgmental targets of $90, $78, and $63 at 25%, 55%, and 20%. The weighted target is a price-only calculation, not a fundamental EV model.

Unknowns: Current regular-session price acceptance, a consistent bid and ask, depth, venue quality, volume quality, realistic exit liquidity, the Q2 10-Q balance-sheet presentation, current debt and lease claims, paid IAM attach, IAM cohort retention, net new ARR, contract duration, deferred revenue conversion, actual repurchase settlement, and the current common denominator are not all verified in one aligned observation.

The Market Price

Observation Value Timestamp / session Source and limitation
Regular-session close $65.97, up $0.58 or 0.89%; open $67.06, high $68.46, low $65.53, volume 5,025,567 Sep. 3, 2026 at 20:00:00 UTC, regular U.S. session DOCU historical price; daily tape, not proof of current depth or exit liquidity
After-hours reference $69.25, about 4.9% above the $66.00 close shown in the same market-structure snapshot; after-hours volume 575,799 Sep. 3, 2026 at 20:59:30 UTC, after-hours DOCU ChartExchange market snapshot; context only, not an executable entry
Displayed after-hours top of book $69.51 bid / $69.73 ask / $0.22 spread Sep. 3, 2026 at 20:59:30 UTC Same ChartExchange snapshot; one thin-session view, depth and venue quality unverified
Conflicting finance-feed observation $65.97; feed also showed a $73.21 high, $61.09 low, open $66.84, volume 5,648,836, and market cap $12.962 billion Sep. 3, 2026 at 23:18:25 UTC DOCU finance quote; does not reconcile with the after-hours snapshot, so its market cap is not used in EV
Current provider context $12.60 billion market cap, $11.97 billion enterprise value, $1.12 billion TTM FCF, $190.94 million shares outstanding Provider update checked Sep. 4, 2026 DOCU statistics; mixed timestamps and provider methodology, context only
Q2 operating output Revenue $875.746 million, OCF $334.546 million, FCF $295.757 million, FCF margin 34% Quarter ended July 31, 2026; released Sep. 3 Docusign SEC Q2 exhibit
Q2 cash and denominator evidence Cash and investments $973.1 million; Q2 repurchases $306.5 million; diluted weighted-average shares 193.117 million July 31, 2026 quarter; released Sep. 3 Docusign SEC Q2 exhibit
Current positioning 15.418832 million shares short, 8.12% of public float, 5.3 DTC, up 1.95% from the prior report Aug. 14, 2026 settlement; published in the Aug. 25 cycle DOCU MarketBeat short interest; biweekly data, not a live position

The quote sources are not interchangeable. The regular close is the cleanest session reference. The after-hours $69.25 observation is used for the scenario map because it is a post-result price observation before the run, but the later finance-feed print at $65.97 shows that the market state is not reconciled. That conflict alone keeps entry.price null. A regular-session quote, current top of book, depth, venue, volume quality, and realistic exit liquidity must be rechecked before any expression could be considered.

The Mispricing

The market is pricing a mature software company with roughly 9% forward growth, real cash generation, high institutional ownership, and a product transition whose financial payoff is not yet visible in the reported revenue line.

What is priced: Low-double-digit or high-single-digit growth, a roughly 34% reported FCF margin, a large cash and investment balance, recurring buybacks, and a mature agreement franchise. The after-hours move indicates that the market recognized the Q2 beat and guide increase, but the quote has not established a new regular-session equilibrium.

What is missing: A proof that IAM is incremental paid ARR rather than packaging, a cash bridge after stock compensation and working capital, a current denominator after repurchases, and evidence that the 18% to 19% IAM exit objective can coexist with stable legacy retention.

The non-consensus view is not that DOCU returns to its former hypergrowth multiple. It is that a business growing revenue about 9% with 31% to 31.5% guided non-GAAP operating margins, positive GAAP operating income, cash and investments near $1 billion, and meaningful share cancellation can earn a better per-share valuation than a static revenue multiple implies. A modest rerating from the after-hours reference to $78 does not require 20% growth. It requires the market to believe that cash and denominator management are durable and that IAM is a real expansion layer.

The market may be right. Docusign's non-GAAP bridge excludes $148.604 million of Q2 stock compensation, and the company expects ARR growth below 10%. AI integrations can increase product utility without increasing price. Contract liabilities can support current cash while future renewal or collections weaken. A 9% guide leaves little room for execution noise at a stock price that has already risen from the low $40s earlier in the year. The long therefore depends on a narrow test, not on an AI narrative.

The Positioning

The latest public short-interest report shows 15.42 million DOCU shares short, or 8.12% of public float, with 5.3 days to cover. Short interest rose 1.95% from the prior report. This is meaningful enough to create marginal demand if the Q3 guide and IAM evidence improve, but not large enough to make a squeeze the thesis. The data are as of the August 14 settlement, so they do not measure the post-result position.

Institutional ownership is reported at approximately 92.68% and insider ownership at 0.53% in the current provider statistics. High institutional ownership can amplify a guide-driven allocation decision, but it also means the next seller can be a large, patient holder rather than a forced short. A good long thesis should survive without short covering.

The after-hours spread snapshot is not sufficient positioning or execution evidence. It shows a displayed spread of $0.22, but it does not show depth behind the quote, venue quality, hidden liquidity, regular-session behavior, or realistic exit size. The finance-feed conflict makes the missing-data penalty explicit. Positioning conclusion: moderate potential flow tension, stale short-interest data, and no verified execution edge.

The Catalyst

The catalyst ladder is observable and ordered:

  1. Regular-session price acceptance: Reconcile the $65.97 regular close, the $69.25 after-hours observation, and any new regular-session bid, ask, spread, depth, venue, and volume-quality data. Acceptance near or above the post-result reference supports the market's initial read. A fast reversal does not automatically disprove the business case, but it removes the near-term timing edge.
  2. Q2 10-Q: The company said it expected to file the July 31 10-Q on September 4. Verify cash and investments, contract liabilities, leases, debt claims, actual shares, repurchases, deferred contract-acquisition costs, and working-capital movements. This is the cheapest balance-sheet and denominator test.
  3. IAM paid conversion: Track whether the 15.1% ARR share advances toward 18% to 19% by FY27 exit, while retention and legacy eSignature remain stable. Require paid attach, expansion, or customer case evidence. A connector or feature launch is not sufficient.
  4. Q3 execution: Compare reported revenue with the $886 million to $890 million guide, operating margin with 31.3% to 31.7%, and cash conversion with the prior quarter. The desired surprise is stable or higher recurring cash after SBC, not a one-quarter working-capital release.
  5. Repurchase and denominator: Reconcile cash paid for repurchases with actual shares cancelled and the next diluted share count. The per-share case is stronger if the company is buying back shares below the value of durable FCF. It is weaker if buybacks merely offset new compensation grants.

The Payoff

The payoff is a price-only distribution. It is deliberately more conservative than a bull-case AI valuation and does not use an EV bridge.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Horizon Conditions Evidence Quality
Top Case 25% $90.00 +29.96% long from $69.25 Through the next Q3 fiscal 2027 result IAM reaches or exceeds its 18% to 19% path, Q3 guide is met or raised, cash after SBC remains positive, and repurchases reduce the actual denominator Medium
Base Case 55% $78.00 +12.64% long from $69.25 Through the next Q3 fiscal 2027 result Revenue stays near the 9% guide, IAM mix progresses, cash remains durable but SBC limits the multiple, and the regular tape accepts the result Medium
Bottom Case 20% $63.00 -9.03% long from $69.25 Through the next Q3 fiscal 2027 result IAM is mostly packaging, growth remains below guide, the Q2 cash bridge weakens after SBC and working capital, or software multiples compress Medium
Invalidation n/a Insufficient data for a responsible numeric level Not a price stop Re-underwrite on the next filing or guide change Q3 guide is cut, IAM share stalls without paid conversion, retention weakens, or actual repurchases fail to reduce the diluted denominator High when filed

Probability-weighted expected price: 0.25 x $90.00 + 0.55 x $78.00 + 0.20 x $63.00 = $78.00.

Probability-weighted gross expected return: $78.00 / $69.25 - 1 = +12.64% before spread, slippage, fees, financing, and carrying costs.

Why net EV cannot be computed: The entry is null, the current quote feeds conflict, the market-cap observation is tied to a different price timestamp, the balance sheet is dated July 31, and the common denominator after the latest repurchase is not aligned in one source. The price-only weighted target is useful for ranking, not for authorizing a trade.

The Kill Shot

The mature counterparty would say that DOCU is being paid twice for the same thing. First, the market values the installed agreement workflow as recurring software. Second, it values AI agents and IAM as a new growth layer, even though the filing reports no separate paid-agent revenue or IAM retention cohort. At the same time, Q2 FCF includes $148.6 million of SBC, so the apparent cash yield is partly the result of paying employees in equity. Buybacks can reduce the denominator, but they also consume cash that could otherwise fund product investment or strengthen the balance sheet. On this view, $69.25 is not cheap; it is a reasonable price for a mature, cash-generative company with a low-growth guide.

That argument is strong. It is why the bottom case is below the 5% adverse bound and why this is not Trade-qualified. The long remains interesting because the company has already demonstrated three things in the filed numbers: high gross margins, positive GAAP operating income, and actual share-count reduction. The question is whether those facts persist while IAM expands. If they do, the market need not believe an aggressive AI story to support a higher per-share value.

Load-bearing assumption: IAM is incremental paid expansion that improves the durability of the existing agreement base rather than a reclassification of existing value.

Cheapest falsification test: Read the Q2 10-Q and next earnings materials for IAM attach, cohort retention, net new ARR, cash after SBC, repurchase settlement, and the diluted denominator. If those data are absent, the thesis loses evidence rather than gaining certainty.

What Could Go Wrong

  • Growth compression: FY27 revenue and ARR growth stay around 9% or fall below guide, and the market assigns a lower mature-software multiple.
  • IAM relabeling: IAM rises as a share of ARR without incremental paid adoption, higher net retention, or larger customer spend.
  • Cash-quality erosion: FCF falls after SBC, deferred contract-acquisition costs, capitalized software, or unfavorable receivable timing are separated.
  • Dilution offset: Repurchases continue, but new equity awards prevent the actual diluted denominator from falling.
  • Competition: Microsoft, Adobe, contract-lifecycle vendors, or internal AI tools commoditize agreement analysis and workflow execution.
  • Working-capital reversal: Contract liabilities and collections supported the quarter, then reverse while revenue remains slow.
  • Market-structure gap: The after-hours reference disappears at the next regular open, the spread widens, or exit liquidity is much worse than the event-day volume suggests.
  • Operational incident: A security, availability, privacy, or compliance event damages customer trust and creates remediation cost.
  • Macro and FX: Enterprise software budgets or foreign exchange reduce demand and reported growth.

What Would Prove This Wrong

Remove the long research case and re-underwrite if any of the following occurs:

  1. The Q2 10-Q shows a material cash, investment, debt, lease, contract-liability, or denominator state that invalidates the cash and share-count bridge.
  2. Q3 revenue or operating-margin guidance is cut below the current $886 million to $890 million and 31.3% to 31.7% ranges without a clearly funded, high-return investment plan.
  3. IAM remains near 15.1% of ARR or rises without paid attach, customer expansion, retention, or incremental ARR evidence.
  4. Reported FCF stays positive only because of working-capital timing while FCF less SBC is persistently weak or negative.
  5. Actual repurchases fail to reduce the diluted denominator after grants, tax withholding, and settlement are reconciled.
  6. A required quote, spread, depth, venue, volume-quality, exit-liquidity, current filing, or denominator check remains missing. In that state, keep entry.price null and execution.can_execute false.

Risk Audit

Risk Why it matters Control
After-hours gap The $69.25 reference may not survive a regular session Do not treat after-hours price as entry; require regular-session acceptance
Quote conflict $69.25 after hours and $65.97 later finance-feed observation are not reconciled Keep entry null until a current quote and top of book agree
Spread and depth A displayed $0.22 spread is one snapshot and does not show executable size Require current spread, depth, venue, volume quality, and realistic exit liquidity
FCF quality $148.6M of Q2 SBC is inside operating cash flow Track reported FCF, SBC, the labeled FCF-less-SBC proxy, working capital, and actual share change separately
Denominator risk Buybacks can coexist with new grants and tax withholding Reconcile shares issued, repurchased, cancelled, diluted shares, and award activity
Growth risk FY27 revenue and ARR guidance is only about 9% Require IAM paid conversion and retention evidence before a rerating claim
Contract-liability timing Upfront collections can make a quarter look stronger Compare deferred revenue, receivables, billings, revenue, and cash across filings
Competition and security Agreement data and workflow trust are core assets Monitor retention, product reliability, legal, privacy, and security disclosures
Gap and halt risk A stop order cannot guarantee a 5% loss boundary Use evidence-backed invalidation and no trade when the scenario bound fails

Best Trade Strategy

Instrument: DOCU common stock on Nasdaq, unlevered only. No options, leverage, margin, or market orders are supported by this note.

Entry state: No executable entry. entry.price remains null. The $69.25 after-hours observation is a reference price only. A future expression would require a fresh regular-session quote, reconciled top of book, acceptable spread, depth, venue, volume quality, realistic exit liquidity, the Q2 10-Q, and a current denominator. A limit-price expression would still be conditional research, not an instruction.

Targets: Reference-only top $90.00, base $78.00, bottom $63.00 at 25% / 55% / 20%. These are scenario levels, not guaranteed outcomes.

Horizon: First regular session after the result through the next reported Q3 fiscal 2027 result. Re-underwrite after the Q2 10-Q, every guide revision, the next IAM and retention disclosure, each repurchase and denominator filing, and any material security or compliance event.

Invalidation: A lower guide, stalled IAM paid conversion, weaker retention, negative cash after the SBC and working-capital bridge, or a denominator that does not improve as expected. A price move alone is not proof of fundamental invalidation, but a persistent market-data failure is an execution block.

Do not trade: Do not buy the after-hours mark, use the weighted target as a promise, rely on the AI feature list, treat reported FCF as residual common cash, treat a buyback authorization as completed demand, or proceed while quote, depth, exit, filing, or denominator evidence is missing. Do not use options to manufacture a maximum-loss claim without a verified live chain and instrument-level model.

Monitoring: The next evidence that matters is paid IAM attach, retention, Q3 guide conversion, cash after SBC and working capital, actual repurchases, and the current diluted denominator. The long case should be downgraded if the market is asked to pay more for the narrative while these measurements remain undisclosed.

Sources

Research Quality Scorecard

Criterion Score Reason
Market disagreement 4/5 Fresh guide and cash evidence meet a still-unsettled post-result price state
Evidence base 5/5 Same-day SEC exhibit supplies operating, cash, balance-sheet, guidance, and denominator inputs
Positioning and flows 4/5 Short interest is meaningful and institutional ownership is high, but data are lagged and no live flow audit exists
Catalyst path 4/5 Regular-session acceptance, the expected 10-Q, IAM conversion, Q3 guide, and repurchase filing are observable
Payoff architecture 4/5 Base case clears +10%, but the adverse case exceeds the 5% bound and net EV cannot be computed
Invalidation discipline 4/5 The cash, IAM, retention, guide, denominator, and execution gates are explicit
Differentiated insight 5/5 The thesis centers on IAM paid conversion and cash after SBC, not generic AI enthusiasm
Client value 4/5 Useful underwriting map even though the correct current action is no trade
Total 34/40 Watchlist research; Reject for current execution

A high score does not override the failed 10/5 gate or incomplete execution evidence.

Bottom Line

Docusign is the best current U.S. long research candidate from this screen because the Sep. 3 filing shows a real combination of 9% growth, rising IAM mix, 34% reported FCF margin, cash and investments near $1 billion, and a materially lower diluted share count. The harder truth is equally important: Q2 stock compensation was $148.6 million, FY27 growth guidance is only about 9%, and the after-hours quote does not reconcile across feeds. The reference-only base case is +12.64%, but the credible bottom case is -9.03% and the gross ratio is 1.40:1. The article is therefore a Watchlist, not a buy signal. The bot must remain blocked until market structure, the Q2 10-Q, IAM paid conversion, cash after SBC, actual repurchases, and the current denominator are verified.

AI Illustration Prompt

Create a restrained, high-end editorial illustration for The Mispricing Desk: a quiet institutional trading desk at night, with a glass terminal showing DOCU $69.25 after hours and a second small quote window showing $65.97 regular close, separated by a thin red discrepancy line. In the foreground, place a signed SEC filing page with three precisely legible figures highlighted: 15.1% IAM ARR, 34% FCF margin, and $148.6M stock compensation. Beside it, show a shrinking stack of translucent share certificates, a modest repurchase ledger, and a small contract document opening into a governed workflow diagram with subtle nodes labeled Agent Studio, MCP, and Workflow Builder. Use charcoal, warm paper, muted cobalt, restrained green for verified cash, and one controlled red accent for the quote conflict. Make the composition forensic, calm, and financially literate, like a Bloomberg Markets or Barron's cover. No generic candlestick chart, no rockets, no neon AI brain, no exaggerated arrows, no promises of profit. Add a subtle etched “The Mispricing Desk” mark along the lower edge of the terminal glass.